Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

IMMP Relative to the S&P 500

IMMP Relative to the Sector

Seasonal Chart Analysis

Analysis of the Immutep Limited (NASD:IMMP) seasonal charts above shows that a Buy Date of March 4 and a Sell Date of June 2 has resulted in a geometric average return of 10.47% above the benchmark rate of the S&P 500 Total Return Index over the past 13 years. This seasonal timeframe has shown positive results compared to the benchmark in 10 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 13 years by an average of 32.52% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK 781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

To download IMMP seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: IMMP